PDC*line Pharma is a clinical-stage Biotechnology company that develops a new class of potent, off-the-shelf therapeutic cancer vaccines based on a proprietary cell line of Plasmacytoid Dendritic Cells (PDC*line). Based on a robust preclinical package and a first-in-human phase Ib in melanoma, PDC*line Pharma reported promising Phase I/II results in lung cancer (PDC*lung) in 2024. Preparations are now underway for a randomized Phase II trial in lung cancer, and a Phase Ib trial in colorectal cancer with neoantigens (PDC*neo). The company has raised €61M in equity and non-dilutive funding and signed a €108M licensing deal in Asia with the Korean pharmaceutical company, LG Chem Life Science.
Company Details
- Employees
- 32
- Founded
- -
- Address
- Pdc*line Pharma Sa, Boulevard Patience Et Beaujonc N°3 Boîte 6, Liège,liège 4000,belgium
- Phone
- +33 (0) 4 84 35 05 04
- co****@****rma.com
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- pdc-line-pharma.com
- Keywords
- Cancer immunotherapy, Therapeutic vaccines, Clinical development, Plasmacytoid Dendritic Cells, neoantigens.
- HQ
- Liège, Liège
Pdc*line Pharma Questions
Pdc*Line Pharma's helpline number is +33 (0) 4 84 35 05 04
Pdc*Line Pharma's website is pdc-line-pharma.com
Pdc*Line Pharma's LinkedIn profile is https://fr.linkedin.com/company/pdc-line-pharma
Pdc*Line Pharma has
32 employees.
View email and phone details for 32
employees at Pdc*Line Pharma.
Pdc*Line Pharma's industry is
Biotechnology Research
Pdc*Line Pharma's top competitors are
Légiapark,
Exo Biologics,
Kiomed Pharma,
Bioxodes,
Novadip Biosciences S.a.,
Hyloris Pharmaceuticals,
Imcyse Sa,
Eyed Pharma,
Amyl Therapeutics,
Trasis.
Pdc*Line Pharma's support email address is contact@pdc-line-pharma.com
Pdc*Line Pharma's categories are Biotechnology Research
Pdc*Line Pharma's founding year is 2014
